Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103720 · ClinicalTrials.gov registry record · Phase 4
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
A Phase 4 study of Allergy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07103720 is a Phase 4 study of Allergy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 328-participant average among 15 other Allergy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07103720, a Phase 4 study of Allergy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Perioperative anaphylaxis is a potentially life-threatening drug allergic reaction that can occur during anesthetic procedures. The purpose of this research is to determine the maximal nonirritating skin testing concentrations of midazolam, ketamine and ondansetron. These drugs are FDA approved and commonly used before, during and after surgical procedures.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Skin Testing
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07103720
The ClinicalTrials.gov registry entry for NCT07103720 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 15 other Allergy trials with a reported enrollment target (82% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergy appearing as the primary indexed condition, and to 1 intervention - of which Skin Testing is the first listed.
NCT07103720 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT07103720 about?
NCT07103720 is a clinical study titled "The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron". Perioperative anaphylaxis is a potentially life-threatening drug allergic reaction that can occur during anesthetic procedures. The purpose of this research is to determine the maximal nonirritating skin testing concentrations of midazolam, ketamine and ondansetron. These drugs are FDA approved and ...
What is the current status of trial NCT07103720?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2025-11-05. Estimated completion is 2026-10-30.
What conditions does trial NCT07103720 study?
This clinical trial studies the following conditions: Allergy.
What interventions are being tested in trial NCT07103720?
The interventions under investigation include: Skin Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07103720?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07103720 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
RECRUITING
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Childhood Allergy and the Neonatal Environment
ACTIVE NOT RECRUITING
-
Urban Environmental Factors and Childhood Asthma
COMPLETED
-
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
COMPLETED · Phase 2
-
Vitamin D, Steroids, and Asthma in African American Youth
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.